Soleno Therapeutics (SLNO) announced the U.S. commercial availability of VYKAT XR extended-release tablets, the company’s treatment for hyperphagia in patients four years of age and older with Prader-Willi syndrome which was approved by the U.S. Food and Drug Administration on March 26, 2025. Prescriptions of VYKAT XR have now been delivered to the first individuals living with PWS who have been prescribed the medication. Soleno has established a comprehensive support program, Soleno ONE, to assist patients, caregivers and healthcare providers with access to VYKAT XR.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Soleno Therapeutics put volume heavy and directionally bearish
- Positive Outlook for Soleno Therapeutics Following FDA Approval and Strong Financial Position
- Soleno Therapeutics price target raised to $100 from $70 at H.C. Wainwright
- Soleno Therapeutics Stock (SLNO) Surges on FDA Green Light for PWS Treatment
- Soleno Therapeutics price target raised to $108 from $74 at Stifel